Company

MediQuest Therapeutics

As of the edition of 20 October 2026, MediQuest Therapeutics runs 1 drug; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet1
Total1

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
GUCY1A2 Guanylate cyclase soluble subunit alpha-2Route A
GUCY1A1 Guanylate cyclase soluble subunit alpha-1Route A
GUCY1B1 Guanylate cyclase soluble subunit beta-1Route A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Heart and blood vessels: 1 trials led
  • Skin and connective tissue: 1 trials led